on Revelation Biosciences, Inc. (NASDAQ:REVB)
Revelation Biosciences Set to Discuss Phase 1b Data in Upcoming Conference Call
Revelation Biosciences, Inc. (NASDAQ:REVB), a company specializing in the rebalancing of inflammation, reminds stakeholders of its upcoming webcast on September 10th. Scheduled for 8:30 am Eastern Time, the discussion will cover top-line data from the PRIME Phase 1b study. Interested parties can join the webcast through the company’s website or dial in using the provided numbers and access code.
The clinical-stage company is focused on its proprietary formulation, Gemini, which targets rebalancing inflammation. Current projects include its use in preventing post-surgical infections, acute kidney injury, and treating chronic kidney disease. The call will provide insights into the progress of these applications.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Revelation Biosciences, Inc. news